Cutaneous adverse reactions to imatinib: a case report of a successful slow protocol for induction of drug tolerance.

Imatinib mesilate (Gleevec, Novartis, UK) is a selective tyrosine kinase inhibitor widely used for the treatment f hematologic diseases such as chronic myeloid leukemia (CML). Administration of imatinib has been related to both cutaneous side effects and hypersensitivity reactions. Since it often is a unique therapeutic option for the treatment of CML, desensitization becames an option in patients who develop hypersensitivity reactions and do not have equally effective therapeutic options. We hereby propose a possible slow protocol for induction of tolerance, suitable for patients who develop cutaneous delayed reactions.